The secondary analysis of a multicenter, randomized, controlled trial in China suggested that maintaining systolic blood pressure (SBP) at <130 mmHg offers additional cardiovascular benefits among young-older patients with high blood pressure. The trial enrolled 8511 young-older (60–80 years) hypertensive patients without prior stroke to compare the intensive treatment (SBP target, 110 to <130 mmHg) versus the standard treatment (130 to <150 mmHg). There are 3053 patients (72.0%) in the intensive-treatment group and 3427 (80.3%) in the standard-treatment group had SBP target achieved (TA), with mean follow-up SBP values of 124.2 mmHg and 137.4 mmHg, respectively. During the median 3.38-year follow-up, the cardiovascular risk was significantly lower in the TA intensive-treatment group than in the TA standard-treatment group (adjusted hazard ratio [HR] 0.61). In the intensive-treatment group, patients failing to achieve SBP targets presented higher cardiovascular risk than those TA patients (HR 2.04). A J-shaped relationship was observed between mean achieved SBP and risk of cardiovascular events, with the lowest risk at an SBP of 126.9 mmHg. The findings support the cardiovascular benefits of maintain SBP <130 mmHg in young-older patients with high blood pressure. Source: https://academic.oup.com/eurjpc/
The American Cancer Society (ACS) concludes that the benefits of PSA-based screening for prostate cancer…
Proton pump inhibitor (PPI) use was modestly associated with incident dementia in older adults (pooled…
Extended follow-up of three major trials consistently shows that an initial invasive strategy does not…
Escitalopram, duloxetine, and agomelatine achieved higher sustained response rates than fluoxetine, while escitalopram and duloxetine…
Targeting a systolic blood pressure (BP) of less than 120 mm Hg lowered the incidence…
In patients with type 2 diabetes (T2D) and high cardiovascular risk, targeting a systolic blood…
This website uses cookies.